Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

Libtayo reached $367M in Q4 global sales ... Sanofi development balance is fully repaid in 2026. Analysts: Slightly positive, ...